

AMENDMENT

In the Claims:

Please cancel claims 1-20.

Please replace the presently pending claims with the following new claims:

21. (New) A method for treating and/or preventing platelet membrane receptor protein gpIIb/IIIa-associated disorders in a mammal, including human, comprising administering to the mammal an amount of adenosine that is effective in inhibiting the activation of platelet membrane receptor protein gpIIb/IIIa.

22. (New) The method of claim 21, wherein the activation of platelet membrane receptor protein gpIIb/IIIa induces platelet aggregation or thrombosis.

23. (New) The method of claim 21, wherein the platelet membrane receptor protein gpIIb/IIIa-associated disorder is a thromboembolic disorder selected from the group consisting of atherosclerosis, arteriosclerosis, acute myocardial infarction, angina, transient ischemic attack, stroke, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism and carotid endarterectomy.

24. (New) The method of any one of claims 21 to 23, further comprising simultaneously or sequentially administering to the mammal an antithrombotic in combination with adenosine.

25. (New) The method of claim 24, wherein said antithrombotic is selected from the group consisting of coumarin, aspirin, heparin, low molecular weight heparin, ticlopidine, hirudin and a thromboxane A₂ synthase inhibitor or receptor antagonist.

26. (New) A pharmaceutical composition for treating and/or preventing platelet membrane receptor protein gpIIb/IIIa-associated disorders in a mammal, including human, comprising an amount of adenosine that is effective in inhibiting the activation of platelet membrane receptor protein gpIIb/IIIa and a pharmaceutically acceptable carrier or diluent.

27. (New) The pharmaceutical composition of claim 26, wherein the activation of platelet membrane receptor protein gpIIb/IIIa induces platelet aggregation or thrombosis.

28. (New) The pharmaceutical composition of claim 26, wherein the platelet membrane receptor protein gpIIb/IIIa-associated disorder is a thromboembolic disorder selected from the group consisting of atherosclerosis, arteriosclerosis, acute myocardial infarction, angina, transient ischemic attack, stroke, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism and carotid endarterectomy.

29. (New) The pharmaceutical composition of any one of claims 26 to 28, further comprising an antithrombotic.

30. (New) The pharmaceutical composition of claim 29, wherein said antithrombotic is selected from the group consisting of coumarin, aspirin, heparin, low molecular weight heparin, ticlopidine, hirudin and a thromboxane A₂ synthase inhibitor or receptor antagonist.

31. (New) A kit for treating and/or preventing platelet membrane receptor protein gpIIb/IIIa-associated disorders in a mammal, including human, comprising a first container containing adenosine and a second container containing a pharmaceutically acceptable carrier or diluent.

32. (New) A kit for treating and/or preventing platelet membrane receptor protein gpIIb/IIIa-associated disorders in a mammal including human, comprising a first container containing adenosine, a second container containing an antithrombotic, and a third container containing a pharmaceutically acceptable carrier or diluent.

33. (New) The kit of claim 32, wherein said antithrombotic is selected from the group consisting of coumarin, aspirin, heparin, low molecular weight heparin, ticlopidine, hirudin and a thromboxane A₂ synthase inhibitor or receptor antagonist.